[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Santiago RJ, Harris EE, Qin L, Hwang WT, Solin LJ: Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience. Cancer; 2005 Jun 15;103(12):2447-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Similar long-term results of breast-conservation treatment for Stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast: The University of Pennsylvania experience.
  • BACKGROUND: The objective of the current study was to determine the long-term results of breast-conservation treatment in women with early-stage, invasive lobular carcinoma of the breast.
  • METHODS: Between 1977 and 1995, 1093 women with Stage I and II invasive ductal carcinoma of the breast and 55 women with invasive lobular carcinoma of the breast underwent lumpectomy, axillary lymph node dissection, and radiation treatment.
  • Overall, 49% of the women received adjuvant systemic therapy (chemotherapy and/or hormones).
  • RESULTS: The median age was 52 years for patients in the invasive ductal group and 54 years for patients in the invasive lobular group.
  • The median follow-up was 8.7 years and 10.2 years for patients in the invasive ductal and invasive lobular groups, respectively.
  • A comparison of patients who had invasive lobular carcinoma with patients who had invasive ductal carcinoma showed no difference in the 10-year actuarial rates of overall survival (85% vs. 79%, respectively; P = 0.73), cause-specific survival (93% vs. 84%, respectively; P = 0.85), or freedom from distant metastases (81% vs. 80%, respectively; P = 0.76).
  • The 10-year rates of local failure were 18% for patients with invasive lobular carcinoma and 12% for patients with invasive ductal carcinoma (P = 0.24), and the 10-year rates of contralateral breast carcinoma development for the 2 groups were 12% and 8%, respectively (P = 0.40).
  • CONCLUSIONS: Breast-conservation treatment yielded similar long-term results for women with early-stage, invasive lobular carcinoma and women with the more prevalent invasive ductal carcinoma.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - invasive ductal carcinoma.
  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15887223.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


2. Bollet MA, Savignoni A, Pierga JY, Lae M, Fourchotte V, Kirova YM, Dendale R, Campana F, Sigal-Zafrani B, Salmon R, Fourquet A, Vincent-Salomon A: High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies. Br J Cancer; 2008 Feb 26;98(4):734-41
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies.
  • The literature reports low rates of breast conservation after neoadjuvant chemotherapy for operable breast cancers not amenable to initial breast-conserving surgery.
  • This study aims to compare the outcome of lobular vs ductal carcinomas after neoadjuvant chemotherapy.
  • Between 1989 and 1999, 750 patients with clinical stage II/IIIA ductal (672) or lobular (78) invasive breast carcinomas were treated at the Institut Curie with primary anthracycline-based polychemotherapy followed by either breast conservation (surgery and/or radiotherapy) or mastectomy.
  • Clinical response to primary chemotherapy was significantly worse for lobular than for ductal carcinomas (47 vs 60%; P=0.04), but only histological grade remained predictive in multivariate analysis.
  • Breast conservation was high for both ductal and lobular carcinomas (65 and 54%; P=0.07), due, in part, to the use of radiotherapy, either exclusive or preoperative, for respectively 26 and 40% of patients.
  • The lobular type had no adverse effect, neither on locoregional control nor on overall survival, even in the group of patients treated with breast conservation.
  • [MeSH-major] Breast Neoplasms / therapy. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / therapy. Mastectomy, Segmental. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Invasiveness. Prognosis. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1998 Feb 20;79(1):27-33 [9495354.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):135-42 [17574805.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):677-85 [10524422.001]
  • [Cites] Br J Cancer. 1957 Sep;11(3):359-77 [13499785.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):41-8 [15625359.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):188-94 [15687361.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1169-77 [15718313.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1348-54 [15817336.001]
  • [Cites] J Clin Oncol. 2005 May 1;23(13):2996-3000 [15860855.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jun;184(6):1774-81 [15908529.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1274-82 [16029782.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5678-85 [16115903.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7265-77 [16145055.001]
  • [Cites] J Radiol. 2005 Sep;86(9 Pt 1):1027-34 [16224343.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8331-9 [16293864.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(2):151-6 [10674880.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1220-9 [10715291.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):602-11 [11157009.001]
  • [Cites] J Magn Reson Imaging. 2001 Jun;13(6):821-9 [11382939.001]
  • [Cites] Breast Cancer Res. 2002;4(3):R3 [12052255.001]
  • [Cites] Ann Surg. 2003 Jan;237(1):26-34 [12496527.001]
  • [Cites] Eur J Cancer. 2003 May;39(8):1089-96 [12736108.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4540-5 [14673041.001]
  • [Cites] Eur J Cancer. 2004 Feb;40(3):342-51 [14746851.001]
  • [Cites] Br J Cancer. 2004 Apr 5;90(7):1349-60 [15054453.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1502-8 [15196533.001]
  • [Cites] Breast Cancer Res Treat. 2004 Jul;86(1):31-7 [15218359.001]
  • [Cites] AJR Am J Roentgenol. 2004 Oct;183(4):1159-68 [15385323.001]
  • [Cites] Bull Cancer. 1987;74(6):641-6 [3435789.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Jul;21(2):325-9 [1648043.001]
  • [Cites] Ann N Y Acad Sci. 1993 Nov 30;698:193-203 [8279757.001]
  • [Cites] Radiology. 1994 Jun;191(3):625-31 [8184038.001]
  • [Cites] Eur J Cancer. 1994;30A(5):645-52 [8080680.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):113-20 [8630916.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Ann Oncol. 2006 Aug;17(8):1228-33 [16740599.001]
  • [Cites] Eur J Cancer. 2006 Sep;42(14):2286-95 [16893641.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):55-62 [17196511.001]
  • [Cites] Br J Cancer. 2007 Jan 29;96(2):341-51 [17133270.001]
  • [Cites] Clin Imaging. 2007 May-Jun;31(3):155-61 [17449375.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jul;104(1):109-14 [17061042.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):13-8 [17449193.001]
  • [Cites] J Surg Oncol. 2007 Nov 1;96(6):474-80 [17640031.001]
  • [Cites] Rontgenpraxis. 1998;51(7):235-42 [9793406.001]
  • (PMID = 18253121.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2259192
  •  go-up   go-down


3. Mazouni C, Hall A, Broglio K, Fritsche H, Andre F, Esteva FJ, Hortobagyi GN, Buzdar AU, Pusztai L, Cristofanilli M: Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy. Cancer; 2007 Feb 1;109(3):496-501
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
  • BACKGROUND: The purpose of the study was to determine the utility of quantitation of the extracellular domain (ECD) of the HER-2/neu receptor in the serum for predicting response to treatment in patients with primary breast cancer receiving neoadjuvant therapy.
  • METHODS: HER-2/neu ECD was measured in sera obtained from 39 patients with HER-2-amplified stage II-III primary breast cancer undergoing neoadjuvant chemotherapy.
  • Patients were randomly assigned to either 4 cycles of paclitaxel followed by 4 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) (n = 10) or to the same chemotherapy with simultaneous weekly trastuzumab for 24 weeks (n = 29).
  • Changes in HER-2 ECD were monitored with the Bayer HER-2/neu assay over 6 months and correlated with pathological response to treatment.
  • RESULTS: Before initiation of chemotherapy, 28.2% of patients had elevated concentration of the HER-2 ECD (>15 ng/mL).
  • A decrease in the median HER-2 ECD levels from baseline to Week 3 and from baseline to Week 6 of chemotherapy was seen regardless of treatment regimen.
  • However, a 9% drop from Week 3 to Week 6 after initial chemotherapy was predictive of pCR (P = .04).
  • CONCLUSION: A decrease in serum HER-2 ECD levels early during treatment was associated with pathological response in patients receiving primary chemotherapy, particularly trastuzumab-based regimens.
  • Serum HER-2 ECD levels may serve to monitor neoadjuvant therapy in HER-2-positive primary breast cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Receptor, ErbB-2 / blood
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / blood. Carcinoma, Lobular / drug therapy. Cyclophosphamide / administration & dosage. Epirubicin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Kinetics. Middle Aged. Neoadjuvant Therapy. Prognosis. Prospective Studies. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17149760.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


Advertisement
4. Sasson AR, Fowble B, Hanlon AL, Torosian MH, Freedman G, Boraas M, Sigurdson ER, Hoffman JP, Eisenberg BL, Patchefsky A: Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation. Cancer; 2001 May 15;91(10):1862-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular carcinoma in situ increases the risk of local recurrence in selected patients with stages I and II breast carcinoma treated with conservative surgery and radiation.
  • BACKGROUND: Lobular carcinoma in situ (LCIS) is a known risk factor for the development of invasive breast carcinoma.
  • However, little is known regarding the impact of LCIS in association with an invasive carcinoma on the risk of an ipsilateral breast tumor recurrence (IBTR) in patients who are treated with conservative surgery (CS) and radiation therapy (RT).
  • The purpose of this study was to examine the influence of LCIS on the local recurrence rate in patients with early stage breast carcinoma after breast-conserving therapy.
  • METHODS: Between 1979 and 1995, 1274 patients with Stage I or Stage II invasive breast carcinoma were treated with CS and RT.
  • The median follow-up time was 6.3 years.
  • LCIS was more likely to be associated with an invasive lobular carcinoma (30 of 59 patients; 51%) than with invasive ductal carcinoma (26 of 1125 patients; 2%).
  • Subsets of patients in which the presence of LCIS was associated with an increased risk of breast recurrence included tumor size < 2 cm (T1), age < 50 years, invasive ductal carcinoma, negative lymph node status, and the absence of any adjuvant systemic treatment (chemotherapy or hormonal therapy) (P < 0.001).
  • LCIS margin status, invasive lobular carcinoma histology, T2 tumor size, and positive axillary lymph nodes were not associated with an increased risk of breast recurrence in these women.
  • CONCLUSIONS: The authors conclude that the presence of LCIS significantly increases the risk of an ipsilateral breast tumor recurrence in certain subsets of patients who are treated with breast-conserving therapy.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Lobular / pathology. Neoplasm Recurrence, Local / diagnosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11346867.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Cohen LF, Breslin TM, Kuerer HM, Ross MI, Hunt KK, Sahin AA: Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol; 2000 Sep;24(9):1266-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy.
  • Sentinel lymph node (SLN) biopsy has been shown to predict axillary metastases accurately in early stage breast cancer.
  • Some patients with locally advanced breast cancer receive preoperative (neoadjuvant) chemotherapy, which may alter lymphatic drainage and lymph node structure.
  • In this study, we examined the feasibility and accuracy of SLN mapping in these patients and whether serial sectioning and keratin immunohistochemical (IHC) staining would improve the identification of metastases in lymph nodes with chemotherapy-induced changes.
  • Thirty-eight patients with stage II or III breast cancer treated with neoadjuvant chemotherapy were included.
  • Our findings indicate that lymph node mapping in patients with breast cancer treated with neoadjuvant chemotherapy can identify the SLN, and SLN biopsy in this group accurately predicts axillary nodal status in most patients.
  • Furthermore, serial sectioning and IHC staining aid in the identification of occult micrometastases in lymph nodes with chemotherapy-induced changes.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma / drug therapy. Carcinoma / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Adult. Aged. Axilla. Biopsy, Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Immunohistochemistry. Keratins / analysis. Lymph Node Excision. Lymphatic Metastasis. Microtomy. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976701.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


6. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buchholz TA, Hortobagyi GN: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol; 2005 Jan 1;23(1):41-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes.
  • PURPOSE: To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome.
  • PATIENTS AND METHODS: The study included 1,034 patients with stage II and III breast cancer who participated in six clinical trials of PC at our institution between 1985 and 2002.
  • Patients with ILC tended to be older (median age, 53 years v 47 years for patients with IDC) and have more hormone-receptor-positive tumors (92% v 62%; P < .001), lower nuclear grade (nuclear grade 3, 16% v 56%; P < .001), and higher stage at diagnosis (10% v 0% with stage IIIB or IIIC disease; P < .001).
  • At a median follow-up time of 70 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival (P = .001).
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / mortality. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Axilla. Bridged Compounds / therapeutic use. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Disease-Free Survival. Humans. Lymph Nodes / pathology. Middle Aged. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / mortality. Taxoids / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Invasive lobular carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2005 Sep 20;23(27):6796; author reply 6796-7 [16170189.001]
  • [ErratumIn] J Clin Oncol. 2013 Aug 10;31(23):2977. Buccholz, Thomas A [corrected to Buchholz, Thomas A]
  • (PMID = 15625359.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


7. Ugnat AM, Xie L, Morriss J, Semenciw R, Mao Y: Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment. Br J Cancer; 2004 Mar 22;90(6):1138-43
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of women with breast cancer in Ottawa, Canada: variation with age, stage, histology, grade and treatment.
  • This study examined the 5-year survival of 2192 breast cancer women diagnosed between 1994 and 1997 in Ottawa, Canada, by age, TNM stage, histology, grade and treatment, including assessment of the independent value of variables in defining prognosis.
  • Our results showed that age, stage, treatment and grade significantly influenced outcome regardless of the confounding factors considered, with histology failing to achieve significant independent prognostic information.
  • The survival rates were highest at ages 50-69 years for stage I and at ages 40-49 years for stages II-IV.
  • The rates were lowest at ages <or=39 years for stages I-II and at ages >or=70 years for stages III-IV.
  • The differences in survival between grade 1 and grade 3 were 9% in stage I and 20% in stage II.
  • The treatment leading to the best survival was surgery plus radiation for stages I-II and surgery combined with chemotherapy for stages III-IV.
  • Lobular carcinoma had a better prognosis than ductal carcinoma; this can be explained by more grade 1 and less grade 3 cases in lobular carcinoma.
  • Stage I patients aged 50-69 years having the best survival is likely due to the earlier diagnosis achieved through screening.
  • [MeSH-minor] Adult. Age Factors. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Histology. Humans. Middle Aged. Multivariate Analysis. Ontario / epidemiology. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 15;88(2):369-74 [10640970.001]
  • [Cites] Stat Med. 1997 Jul 15;16(13):1435-49 [9249917.001]
  • [Cites] Tumori. 2000 Mar-Apr;86(2):119-23 [10855847.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):267-72 [10962458.001]
  • [Cites] J Natl Cancer Inst. 1982 Aug;69(2):349-55 [6955542.001]
  • [Cites] Stat Med. 1990 May;9(5):529-38 [2349404.001]
  • [Cites] CMAJ. 1992 Nov 15;147(10):1477-88 [1423088.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):35-42 [7999467.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):406-21 [8001011.001]
  • [Cites] Int J Cancer. 1995 Jul 17;62(2):138-44 [7622286.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] Tumori. 1996 Sep-Oct;82(5):441-3 [9063519.001]
  • [Cites] Eur J Cancer. 1997 Mar;33(3):425-8 [9155527.001]
  • [Cites] Aust N Z J Public Health. 1997 Apr;21(2):199-205 [9161078.001]
  • [Cites] J Am Coll Surg. 2000 May;190(5):523-9 [10801018.001]
  • (PMID = 15026792.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2409653
  •  go-up   go-down


8. Olson JA Jr, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS Jr, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ: Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg; 2009 May;208(5):906-14; discussion 915-6
Hazardous Substances Data Bank. LETROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.
  • BACKGROUND: Neoadjuvant aromatase inhibitor therapy has been reported to improve surgical outcomes for postmenopausal women with clinical stage II or III hormone receptor-positive breast cancer.
  • A multicenter phase II clinical trial was conducted to investigate the value of this approach for US surgical practice.
  • RESULTS: One hundred six patients were eligible for primary analysis, 96 underwent operations, 7 received chemotherapy after progressive disease, and 3 did not undergo an operation.
  • [MeSH-major] Aromatase Inhibitors / administration & dosage. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy. Neoadjuvant Therapy. Nitriles / administration & dosage. Triazoles / administration & dosage
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Humans. Mastectomy, Segmental. Middle Aged. Multivariate Analysis. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1055-75 [13472656.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6622-8 [15475452.001]
  • [Cites] Endocr Relat Cancer. 2004 Mar;11(1):85-96 [15027887.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1527-32 [11822750.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(30):96-102 [11773300.001]
  • [Cites] IEEE Trans Med Imaging. 2001 Sep;20(9):854-67 [11585203.001]
  • [Cites] Cancer Control. 2000 Nov-Dec;7(6):557-62 [11088064.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2229-35 [10873072.001]
  • [Cites] Cancer. 2000 May 1;88(9):2054-60 [10813717.001]
  • [Cites] J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8 [18812550.001]
  • [Cites] J Clin Oncol. 2008 Feb 10;26(5):778-85 [18258986.001]
  • [Cites] Semin Oncol. 2006 Dec;33(6):650-6 [17145344.001]
  • [Cites] Cancer. 2006 May 15;106(10):2095-103 [16598749.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2019-27 [16606972.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):257-64 [16432360.001]
  • [Cites] Radiology. 2004 Dec;233(3):830-49 [15486214.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5108-16 [15998903.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):60-2 [15639680.001]
  • (PMID = 19476859.001).
  • [ISSN] 1879-1190
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA068438; United States / NCI NIH HHS / CA / R01 CA095614; United States / NIGMS NIH HHS / GM / U19 GM061388; United States / NCI NIH HHS / CA / 3P50 CA68438-07S2
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ NIHMS460618; NLM/ PMC3683862
  •  go-up   go-down


9. Reitsamer R, Peintinger F, Rettenbacher L, Prokop E: Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy. J Surg Oncol; 2003 Oct;84(2):63-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
  • The aim of this study was to evaluate the accuracy and the feasibility of SLNB in breast cancer patients who had received preoperative (neoadjuvant) chemotherapy.
  • METHODS: Patients with advanced breast cancer stage II or III who were treated with neoadjuvant chemotherapy were included in the study.
  • Sentinel lymph node (SLN) identification and biopsy was attempted and performed, and axillary lymph node dissection (ALND) was performed in the same surgical procedure after SLNB.
  • The accuracy of SLNB after neoadjuvant chemotherapy is similar to patients with primary surgery.
  • SLNB could be an alternative to ALND in a subgroup of patients after neoadjuvant chemotherapy, and therefore could reduce morbidity due to surgery in those patients.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Node Excision. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Axilla. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoadjuvant Therapy. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 Wiley-Liss, Inc.
  • (PMID = 14502778.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Cutuli B, Aristei C, Martin C, Perrucci E, Latini P, Quetin P: Breast-conserving therapy for stage I-II breast cancer in elderly women. Int J Radiat Oncol Biol Phys; 2004 Sep 1;60(1):71-6
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-conserving therapy for stage I-II breast cancer in elderly women.
  • PURPOSE: To assess breast-conserving therapy results in elderly patients with early-stage breast cancer (clinical Stage I-II).
  • METHODS AND MATERIALS: Between 1979 and 1998, 196 women (200 treated breasts) aged > or =70 years (median age, 72.5 years) were treated with breast-conserving therapy (lumpectomy or quadrantectomy with axillary lymph node dissection and radiotherapy).
  • Two-thirds of patients received tamoxifen, and 16% received chemotherapy.
  • RESULTS: At a median follow-up of 59 months, 3 patients (1.5%) had developed local recurrence and 20 (10.2%) distant metastases.
  • In another 5 patients, a thromboembolic event occurred during tamoxifen treatment.
  • CONCLUSION: Elderly women tolerate breast-conserving therapy, including radiotherapy, well and have excellent rates of locoregional control and disease-specific survival.
  • [MeSH-minor] Age Factors. Aged. Aged, 80 and over. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / radiotherapy. Carcinoma, Lobular / secondary. Carcinoma, Lobular / surgery. Female. Humans. Mastectomy, Segmental. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15337541.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Mladenovic J, Susnjar S, Gavrilovic D, Borojevic N: Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients. J BUON; 2007 Apr-Jun;12(2):215-20
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postmastectomy radiotherapy in intermediate risk stage I-II breast cancer patients.
  • PURPOSE: To evaluate the correlation of postmastectomy radiotherapy (PMRT) with local relapse rate, disease-free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) patients at intermediate risk for locoregional relapse (stage I-II with either 1-3 positive axillary nodes, or node-negative grade III BC) treated with radical mastectomy.
  • PATIENTS AND METHODS: We evaluated 482 stage I-II BC patients, with either node-negative grade 3 tumors or with 1-3 positive nodes irrespective of tumor grade, treated with radical mastectomy at our Institute from 1986 to 1994.
  • After mastectomy they received either adjuvant CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (N=172), or adjuvant endocrine therapy (N=310).
  • Postoperative radiotherapy (RT group) to the regional lymph nodes with tumor dose (TD) 48 Gy in 22 fractions was delivered to 199 patients.
  • CONCLUSION: Our results did not show that PMRT significantly influences the incidence of disease relapse, DFS and OS in stage I-II BC patients with intermediate risk for disease relapse.
  • [MeSH-major] Breast Neoplasms / radiotherapy. Carcinoma, Ductal / radiotherapy. Carcinoma, Lobular / radiotherapy. Mastectomy. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17600875.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


12. Aukema TS, Straver ME, Peeters MJ, Russell NS, Gilhuijs KG, Vogel WV, Rutgers EJ, Olmos RA: Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Eur J Cancer; 2010 Dec;46(18):3205-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
  • PURPOSE: The aim of this prospective study was to assess the incidence of extra-axillary lymph node involvement on baseline FDG PET/CT in patients with stage II-III breast cancer scheduled for neo-adjuvant chemotherapy.
  • METHODS: Patients with invasive breast cancer of >3 cm and/or proven axillary lymph node metastasis were included for before neo-adjuvant chemotherapy.
  • Radiotherapy treatment was altered in 7 patients with extra-axillary involvement (12% of the total group).
  • CONCLUSIONS: FDG PET/CT detected extra-axillary lymph node involvement in almost one-third of the patients with stage II-III breast cancer, including regions not evaluable with ultrasound.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Carcinoma, Lobular / secondary. Fluorodeoxyglucose F18. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Biopsy, Fine-Needle. Chemotherapy, Adjuvant. Female. Humans. Lymphatic Metastasis / radionuclide imaging. Middle Aged. Positron-Emission Tomography / methods. Prospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20719497.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


13. Gonzalez-Angulo AM, Kau SW, Broglio K, Buzdar AU, Theriault RL, Valero V, Sneige N, Frye D, Hortobagyi GN, Cristofanilli M: Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features. J Clin Oncol; 2004 Jul 15;22(14_suppl):663

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive lobular carcinoma (ILC) "classic type": Distinct clinical features.
  • Induction chemotherapy (IC) is used to downstage tumors and facilitate breast conservative surgery.
  • METHODS: 1034 patients (pts) with stage II and III BC participated in six clinical trials using IC at M.D.
  • All pts received anthracycline-based chemotherapy and 246 pts (23.8%) also received a taxane. pCR was defined as no evidence of invasive BC in the breast and axillary lymph nodes.
  • The stratified log-rank test was used to assess differences between OS and RFS among the groups and after adjustments for hormone receptor (HR) status, stage, and pCR.
  • The lobular group tended to be older (med, 53 vs. 47 yrs), have more HR positive tumors, (92% vs. 62%) lower nuclear grade (16% vs. 56% grade 3), and higher stage at diagnosis (10% vs. 0% were IIIB and IIIC).
  • These differences persisted after adjustment for HR status (p=0.02 and 0.03) and stage (both p=0.04).
  • CONCLUSION: ILC is a distinct histological type of breast cancer characterized by better outcome when compared to IDC in spite of the low pCR rate after IC.
  • The role of primary hormonal therapy should be assessed in ILC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28017095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Dubray P, Durando X, Abrial C, Mouret-Reynier M, Nayl B, Thivat E, Gimbergues P, Achard J, Chollet P, Penault-Llorca F: Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100- docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preferential pathologic complete response (pCR) in HER-2 positive and triple-negative breast cancer to sequential FEC 100- docetaxel (T) neoadjuvant chemotherapy (NCT) in stage II-III operable breast cancer.
  • This chemotherapy is currently the reference in the adjuvant setting in France.In PACS 01 trial (Roche et al.
  • METHODS: 101 patients (pts) from February 2005 to September 2008 with stage II-III operable breast cancer received 3 cycles (c) of FEC 100 (epirubicin 100 mg/m<sup>2</sup> + 5-fluorouracil and cyclophosphamide 500mg/m<sup>2</sup>) followed by 3 c of T (100mg/m<sup>2</sup>) every 3 weeks. pCR was defined according to Chevallier's (Am J Clin Oncol, 1993) as level 1 and 2 and to Sataloff's classification (J Am Coll Surg, 1995) as grade A.
  • 83 pts had a ductal, 14 a lobular, 3 ductal and lobular, 1 another carcinoma.
  • 8.9% were grade I SBR, 58.4% grade II SBR, 28.7% grade III SBR and 4% unspecified.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Khosravi-Shahi P, Izarzugaza Peron Y, Perez-Manga G: Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials. J Clin Oncol; 2009 May 20;27(15_suppl):601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low pathologic complete response (pCR) rate to neoadjuvant chemotherapy in invasive lobular carcinoma of breast: Analysis of subgroup of four phase II trials.
  • : 601 Background: Pathologic complete response (pCR) after preoperative chemotherapy (PCT) is associated with better outcome in locally advanced breast cancer (LABC).
  • METHODS: Patients (p) with histologically confirmed lobular carcinoma (LC), including in four phase II trials (AT, ATX, TXH, and BTX) conducted in our center, were eligible.
  • Radiotherapy (RT) and hormone therapy (Ht) were allowed after surgery.
  • Sixteen ps had LC (16/185 = 8.65%): median age = 50 y (38-66); premenopausal = 56.2%; left breast = 56.2%; median clinical (c) tumor size = 5 cm (3-6); stage:IIA = 6.7%; IIB = 26.7%; IIIA = 33.3%; IIIB = 33.3%; T:cT3 = 50%; cT4 = 28.6%; cN+ = 71.4% (median pN = 2 [0-32]); grade: G2 = 60%, G3 = 40%; ER+ = 78.6%; PgR+ = 64.3%; HER-2+ = 6.25%; phenotype by IHC: Luminal (HR+/HER-2-) = 75% (12/16); Luminal/HER-2+ (HR+/HER-2+) = 6.25%; triple negative (3/16) = 18.75%; p53+ = 25%; EGFR negative = 90%; median Ki-67 = 20% (5-70); adjuvant trastuzumab (H) = 6.25%; RT = 60%, median dose = 50Gy; Ht = 78.6% (tamoxifen = 55%; AI = 45%); type of PCT: docetaxel (T), capecitabine (X), and H (TXH) = 1p (6.2%); doxorubicin (A), T, and X (ATX) = 5 ps (31.2%); bevacizumab, T, and X (BTX) = 5 ps (31.2%); AT = 5 ps (31.2%); median of 5 cycles (2-6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961466.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Von Drygalski A, Tran TB, Messer K, Pu M, Corringham S, Nelson C, Ball ED, Ball ED: Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT). J Clin Oncol; 2009 May 20;27(15_suppl):e22086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of survival in patients with metastatic breast cancer (MBC) treated with high-dose chemotherapy and autologous stem cell transplantation (HD-ASCT).
  • : e22086 Background: Individualized care in MBC requires predictors of survival for tailored treatment.
  • METHODS: Age, race, stage at diagnosis, histology, estrogen receptor (ER) and menopausal status, body mass index (BMI) in kg/m2, time to transplant and death, sites of metastasis, disease status prior to and after transplant, and days in hospital were extracted.
  • Brookmeyer & Crowley's 95% confidence intervals, Cox models for predictors of a time-to-event variable and Schoenfeld tests for proportional hazard assumptions were applied.
  • Stratified by ER status, stage at diagnosis was an independent predictor of OS.
  • Patients with stage I at diagnosis were at lowest risk of death when compared to stage II-IV patients with HRs of 2.7 (II vs I CI 1.4-5.2), 4.6 (III vs I CI 2.1-10) and 17 (IV vs I CI 6.1- 47.8).
  • Death risk was increased with BMI ≥ 30 (HR 3.1; CI 1.8-5.4), infiltrating lobular carcinoma (HR 2.5; CI 1.1-5.38) and visceral metastasis (HR 2.3; CI 1.3-4.1).
  • Obesity, late stage at diagnosis, lobular infiltrating histology and visceral metastasis were independent negative predictors of OS.
  • These data may be useful stratification tools for future trials employing HD-ASCT as treatment modality in MBC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963264.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H, Austrian Breast And Colorectal Cancer Study Group: Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients. Onkologie; 2003 Apr;26(2):115-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
  • AIM: A randomised, controlled clinical trial was initiated in 1984 to test whether 1 cycle of anthracycline-containing adjuvant chemotherapy improves the outcome of breast cancer patients presenting with stage II disease and negative oestrogen and progesterone receptors (ER, PgR), as compared with 6 cycles of dose-reduced CMF.
  • PATIENTS AND METHODS: Within 7 years 263 women with stage II breast cancer were randomised either to receive 1 cycle of doxorubicin, vinblastine, cyclophosphamide, methotrexate and 5- fluorouracil (AV-CMF) or to receive 6 cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
  • Patients were stratified for tumour stage, nodal stage, menopausal status, type of surgery and participating centre.
  • CONCLUSIONS: Compared to 6 cycles of a non-standard low-dose CMF regimen 1 cycle of anthracycline- containing adjuvant chemotherapy failed to improve the outcome in women with stage II receptor-negative breast cancer in terms of DFS and OS.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Drug Administration Schedule. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Lymphatic Metastasis. Methotrexate / adverse effects. Methotrexate / therapeutic use. Middle Aged. Neoplasm Staging. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Survival Rate. Vincristine / adverse effects. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger GmbH, Freiburg
  • [CommentIn] Onkologie. 2003 Apr;26(2):111-2 [12771517.001]
  • (PMID = 12771518.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Evaluation Studies; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate; CMF protocol; CMFDV protocol
  •  go-up   go-down


18. Reitsamer R, Menzel C, Glueck S, Rettenbacher L, Weismann C, Hutarew G: Sentinel lymph node biopsy is precise after primary systemic therapy in stage II-III breast cancer patients. Ann Surg Oncol; 2010 Oct;17 Suppl 3:286-90
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel lymph node biopsy is precise after primary systemic therapy in stage II-III breast cancer patients.
  • SLNB for axillary staging after primary systemic therapy (PST) is still under discussion because of possibly reduced accuracy, while data are lacking.
  • MATERIALS AND METHODS: A total of 185 breast cancer patients were treated with PST; 160 patients received preoperative chemotherapy, and 25 patients received preoperative endocrine therapy.
  • Thus, 143 of 160 patients with preoperative chemotherapy and 22 of 25 patients with preoperative endocrine therapy were eligible for evaluation.
  • RESULTS: Pathologic complete response rates and breast conserving therapy rates were 15.4 and 78.3% in the preoperative chemotherapy group and 0 and 77.3% in the preoperative endocrine therapy group, respectively.
  • Identification rate, sensitivity, overall accuracy, and false-negative rate were 81.1% (116 of 143), 91.7% (55 of 60), 95.7% (111 of 116), and 8.3% (5 of 60) in the preoperative chemotherapy group and 77.3% (17 of 22), 90.0% (9 of 10), 94.1% (16 of 17), and 10.0% (1 of 10) in the preoperative endocrine therapy group, respectively.
  • DISCUSSION: SLNB after primary systemic therapy is accurate, and the results are comparable to those of primary SLNB.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / secondary. Carcinoma, Ductal, Breast / surgery. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / secondary. Carcinoma, Lobular / surgery. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Neoplasm Staging. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20853048.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Schmid P, Krocker J, Schulz CO, Michniewicz K, Dieing A, Eggemann H, Heilmann V, Blohmer JU, Sezer O, Elling D, Possinger K: Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial. Anticancer Drugs; 2005 Jan;16(1):21-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
  • The primary objective was to determine the optimal doses for gemcitabine (prolonged infusion), liposomal doxorubicin (Myocet) and docetaxel as primary (neoadjuvant) chemotherapy for locally advanced breast cancer.
  • Patients (n=19) with histologically confirmed stage II or III breast cancer were treated with liposomal doxorubicin (50-60 mg/m2) and docetaxel (60-75 mg/m2) on day 1, and gemcitabine as 4-h infusion (350-400 mg/m2) on day 4.
  • Treatment was repeated every 3 weeks for a maximum of 6 cycles.
  • The evaluated schedule is suitable for phase II studies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Deoxycytidine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Humans. Maximum Tolerated Dose. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15613900.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


20. Reitsamer R, Peintinger F, Prokop E, Hitzl W: Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer. Anticancer Drugs; 2005 Sep;16(8):867-70
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathological complete response rates comparing 3 versus 6 cycles of epidoxorubicin and docetaxel in the neoadjuvant setting of patients with stage II and III breast cancer.
  • We conducted a prospective randomized study to compare the results of 3 cycles of epidoxorubicin/docetaxel to 6 cycles of epidoxorubicin/docetaxel prior to surgery in breast cancer patients with clinical stages II and III.
  • Forty-five patients eligible for neoadjuvant chemotherapy were randomly assigned to receive either 3 (group 1) or 6 (group 2) cycles of epidoxorubicin/docetaxel prior to surgery.
  • Chemotherapy consisted of epidoxorubicin 75 mg/m and docetaxel 75 mg/m on day 1 in 3-week cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Chemotherapy, Adjuvant. Drug Administration Schedule. Epirubicin / administration & dosage. Epirubicin / analogs & derivatives. Female. Glucuronates / administration & dosage. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Prospective Studies. Receptor, ErbB-2 / metabolism. Remission Induction. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Anticancer Drugs. 2006 Mar;17(3):363
  • (PMID = 16096435.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glucuronates; 0 / Taxoids; 0 / epidoxorubicin glucuronide; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Shamseddine A, Khalifeh M, Chehal A, Saliba T, Mourad YA, Taher A, Jalloul R, Bitar N, Dandashi A, Abbas J, Geara FB: A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC). Am J Clin Oncol; 2005 Aug;28(4):393-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC).
  • This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients.
  • METHODS: Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III).
  • For the locally advanced breast cancer group, the overall response rate was 92.3% with a median time to disease progression of 26 months (range 25-27).
  • Toxicity was acceptable, and no treatment-related mortality was encountered.
  • CONCLUSIONS: PVn is effective as first line treatment of advanced breast cancer with overall response rate of 64% in metastatic breast cancer and 92.3% in locally advanced breast cancer, and acceptable toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adult. Aged. Bone Neoplasms / secondary. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / mortality. Carcinoma, Ductal / pathology. Carcinoma, Ductal / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / secondary. Cisplatin / administration & dosage. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Pilot Projects. Skin Neoplasms / secondary. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINORELBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16062082.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


22. Cuan Martínez JR, Mainero Ratchelous FE, Aguilar Gallegos IU, Bernechea Miranda A, Buenrostro Pineda MA, Burgos Portillo I, Cortés Herrera AE, Burguete Vera JJ: [Comparative study of clinical and pathological features of breast cancer in women with 40 years old and younger vs 70 years old and older]. Ginecol Obstet Mex; 2008 Jun;76(6):299-306
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Comparación de las características de pacientes de 40 o menos y 70 años o más de edad con carcinoma mamario.
  • OBJECTIVE: To compare clinical and radiological characteristics on initial appraisal, as well as surgical treatment, pathological features and adjuvant treatment in women with primary breast cancer of 40 years old and younger vs 70 years old and older.
  • Most frequent histological type in both groups was infiltrating ductal carcinoma, followed by infiltrating lobular carcinoma, most common in older women (19 vs 12%), and we found more well differentiated ductal carcinomas in the group of 70 years old and older (12 vs 4%).
  • Seventy-six percent of group 1 and 75% of group 2 were classified as early stage breast cancer (stages I and II).
  • Cytotoxic therapy was offered mostly to group 1, 92 vs 35%.
  • Radiotherapy (80 vs 59%), and hormonal therapy was given only to 56% of group 1 vs 80% of group 2.
  • There was a trend to perform more conservative surgery at group 1, as well as they underwent more adjuvant chemotherapy and radiotherapy.
  • Use of hormonal therapy was more common at group 2.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18800585.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


23. Perez EA, Geeraerts L, Suman VJ, Adjei AA, Baron AT, Hatfield AK, Maihle N, Michalak JC, Kuross SA, Kugler JW, Lafky JM, Ingle JN: A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Ann Oncol; 2002 Aug;13(8):1225-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.
  • This randomized two-stage phase II study was conducted to evaluate sequential treatment with docetaxel and AC as first-line treatment in patients with recurrent or metastatic breast cancer previously untreated with chemotherapy for metastatic disease.
  • In addition, we compared pre-treatment serum sErbB1 and sErbB2 protein concentrations with that of an age- and menopausal status-matched group of healthy women, and examined changes in serum sErbB1 and sErbB2 protein concentrations in these two treatment schedules.
  • RESULTS: Enrollment was suspended after the first-stage of accrual, based on statistical design.
  • Confirmed objective response rates after six cycles of treatment were 35% [95% confidence interval (CI) 14% to 62%] with docetaxel then AC and 38% (95% CI 15% to 65%) with AC then docetaxel.
  • Median survival time was 2.5 years in the docetaxel then AC group, and 1.1 years in the AC then docetaxel group.
  • Serum sErbB1 concentrations were not significantly different between the study patients and healthy women, and did not change significantly after three and six cycles of treatment.
  • In contrast, serum sErbB2 concentrations were significantly higher in the study patients compared with healthy women and tended to decrease after three and six cycles of treatment.
  • CONCLUSIONS: Response rates at the end of six cycles of treatment, which led to termination of accrual after the first stage using either the sequence of docetaxel first or docetaxel after AC chemotherapy, were lower than anticipated.
  • However, median survival times and median progression-free survival times are similar to those reported in other studies.
  • These data further suggest that additional studies to assess whether serum sErbB2 concentrations are useful predictors of responsiveness to chemotherapy are warranted.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12181246.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-25224; United States / NCI NIH HHS / CA / CA-34515; United States / NCI NIH HHS / CA / CA-35101; United States / NCI NIH HHS / CA / CA-35103; United States / NCI NIH HHS / CA / CA-35195; United States / NCI NIH HHS / CA / CA-35269; United States / NCI NIH HHS / CA / CA-35448; United States / NCI NIH HHS / CA / CA-37404; United States / NCI NIH HHS / CA / CA-37417; United States / NCI NIH HHS / CA / CA-60276; United States / NCI NIH HHS / CA / CA-63849; United States / NCI NIH HHS / CA / CA-76170; United States / NCI NIH HHS / CA / CA-82091; United States / NCI NIH HHS / CA / CA-82520; United States / NCI NIH HHS / CA / CA-85133
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


24. Hausmaninger H, Morack G, Heinrich B, Wallwiener D, Höffken K, Buksmaui S, Krejcy K, Miller MA, Possinger K: Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. Am J Clin Oncol; 2004 Aug;27(4):429-35
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
  • This phase II study of gemcitabine and epirubicin evaluated the activity and toxicity in advanced breast cancer.
  • Female patients with stage IIIB or IV breast cancer received gemcitabine 1000 mg/m2 and then epirubicin 15 mg/m2 on days 1, 8, and 15 of 28-day cycles.
  • Thirty-five patients with stage IV disease, a median age of 59 years (range, 39-73), and a median Karnofsky performance status of 90 (range, 60-100) were enrolled.
  • Fourteen (40.0%) patients received prior chemotherapy (12 adjuvant, 4 metastatic, 2 both).
  • Median time to progression and overall survival were 5.8 months (95% CI, 3.4-9.5 months) and 17.1 months (95% CI, 11.2-19.9 months), respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Lobular / drug therapy. Deoxycytidine / analogs & derivatives

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15289740.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


25. Fowble B, Hanlon A, Freedman G, Nicolaou N, Anderson P: Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):679-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk.
  • PURPOSE: To assess the risk and patterns of second malignancy in a group of women treated with conservative surgery and radiation in a relatively contemporary manner for early-stage invasive breast cancer, and to identify a subgroup of these women at increased risk for a second cancer.
  • METHODS AND MATERIALS: From 1978 to 1994, 1,253 women with unilateral Stage I-II breast cancer underwent wide excision, axillary dissection, and radiation.
  • Adjuvant therapy consisted of chemotherapy in 19%, tamoxifen in 19%, and both in 8%.
  • Factors analyzed for their association with the cumulative incidence of all second malignancies, contralateral breast cancer, and non-breast cancer malignancy were: age, menopausal status, race, family history, obesity, smoking, tumor size, location, histology, pathologic nodal status, region(s) treated with radiation, and the use and type of adjuvant therapy.
  • RESULTS: One hundred seventy-six women developed a second malignancy (87 contralateral breast cancers at a median interval of 5.8 years, and 98 non-breast cancer malignancies at a median interval of 7.2 years).
  • There was no significant effect of chemotherapy or the regions treated with radiation on contralateral breast cancer or non-breast cancer second malignancy.
  • The most common types of second non-breast cancer malignancies were skin cancers, followed by gynecologic malignancies (endometrial), and gastrointestinal malignancies (colorectal and pancreas).
  • The majority of patients treated with conservative surgery and radiation with or without adjuvant systemic therapy will not develop a second cancer.
  • [MeSH-minor] Adult. Age Factors. Aged. Axilla. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / epidemiology. Carcinoma, Lobular / radiotherapy. Carcinoma, Lobular / surgery. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Lymph Node Excision. Lymphatic Irradiation. Mastectomy, Segmental. Middle Aged. Risk. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11597809.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


26. Yoney A, Kucuk A, Unsal M: Male breast cancer: a retrospective analysis. Cancer Radiother; 2009 Apr;13(2):103-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: To evaluate our results in the treatment of male breast cancer patients with respect to local control (LC), overall survival (OS) and possible prognosis factors for survival.
  • Among them, 94.8% had invasive ductal carcinoma (IDC), 2.6% invasive papillary carcinoma (IPC) and 2.6% invasive lobular carcinoma (ILC) and the distribution according to stage was found to be 12.8, 46.2, 30.7 and 10.3% in Stages I, II, III and IV, respectively.
  • Among the patients, 7.7% received radiotherapy (RT) and hormonotherapy (HT), 22.8% received chemotherapy (CT), 61.8% received chemoradiotherapy (CRT) and HT and 7.7% received HT in addition to surgery.
  • In our series, univariate analysis for OS demonstrated statistical significance for lymph node metastases (p=0.00001), stage (p=0.0098) and age (p=0.03); while RT in the treatment modality (p=0.6849), and tumor size (p=0.4439) demonstrated no significance.
  • [MeSH-major] Breast Neoplasms, Male / mortality. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / therapy. Carcinoma, Lobular / mortality. Carcinoma, Lobular / pathology. Carcinoma, Lobular / therapy. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / therapy. Disease-Free Survival. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local. Retrospective Studies

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19250851.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  •  go-up   go-down


27. Zeeneldin AA, Mohamed AM, Abdel HA, Taha FM, Goda IA, Abodeef WT: Survival effects of cyclooxygenase-2 and 12-lipooxygenase in Egyptian women with operable breast cancer. Indian J Cancer; 2009 Jan-Mar;46(1):54-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sections from BC and nearby normal tissues were examined for expression of COX-2 and 12-LOX using reverse transcriptase polymerase chain reaction.
  • Stage II and III disease represented 25 and 75% respectively.
  • Adjuvant chemotherapy, radiotherapy and tamoxifen were used in 90, 75 and 60% respectively.
  • Patients with higher TNM stage or who developed visceral metastases had significantly higher COX-2 expression.
  • [MeSH-major] Arachidonate 12-Lipoxygenase / metabolism. Breast Neoplasms / enzymology. Carcinoma, Ductal, Breast / enzymology. Carcinoma, Lobular / enzymology. Cyclooxygenase 2 / metabolism
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Egypt. Female. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19282568.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] EC 1.13.11.31 / Arachidonate 12-Lipoxygenase; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


28. Beadle BM, Woodward WA, Tucker SL, Outlaw ED, Allen PK, Oh JL, Strom EA, Perkins GH, Tereffe W, Yu TK, Meric-Bernstam F, Litton JK, Buchholz TA: Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach. Int J Radiat Oncol Biol Phys; 2009 Mar 1;73(3):734-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year recurrence rates in young women with breast cancer by locoregional treatment approach.
  • The goal of this study is to determine the impact of locoregional treatment strategy, breast-conserving therapy (BCT), mastectomy alone (M), or mastectomy with adjuvant radiation (MXRT), on LRR for patients 35 years or younger.
  • METHODS AND MATERIALS: Data for 668 breast cancers in 652 young patients with breast cancer were retrospectively reviewed; 197 patients were treated with BCT, 237 with M, and 234 with MXRT.
  • In the entire cohort, 10-year actuarial LRR rates varied by locoregional treatment: 19.8% for BCT, 24.1% for M, and 15.1% for MXRT (p = 0.05).
  • In patients with Stage II disease, 10-year actuarial LRR rates by locoregional treatment strategy were 17.7% for BCT, 22.8% for M, and 5.7% for MXRT (p = 0.02).
  • In patients with Stage I disease, there was no difference in LRR rates based on locoregional treatment (18.0% for BCT, 19.8% for M; p = 0.56), but chemotherapy use had a statistically significant LRR benefit (13.5% for chemotherapy, 27.9% for none; p = 0.04).
  • CONCLUSIONS: Young women have high rates of LRR after breast cancer treatment.
  • For patients with Stage II disease, the best locoregional control rates were achieved with MXRT.
  • For patients with Stage I disease, similar outcomes were achieved with BCT and mastectomy; however, chemotherapy provided a significant benefit to either approach.

  • Genetic Alliance. consumer health - TEN.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1688-97 [11250998.001]
  • [Cites] Cancer. 2007 May 15;109(10):1957-64 [17394192.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):3-10 [3335459.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Apr;14(4):659-63 [3350720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):271-6 [3403310.001]
  • [Cites] Helv Chir Acta. 1989 Apr;55(6):837-42 [2753724.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):591-8 [2313329.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):888-94 [8164038.001]
  • [Cites] J Natl Cancer Inst Monogr. 1994;(16):35-42 [7999467.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Feb 15;31(4):765-75 [7860387.001]
  • [Cites] J Natl Cancer Inst. 1996 Nov 20;88(22):1659-64 [8931610.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):859-67 [9531371.001]
  • [Cites] J Am Coll Surg. 1998 Jul;187(1):1-8 [9660018.001]
  • [Cites] Lancet. 2005 Dec 17;366(9503):2087-106 [16360786.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):351-6 [16314086.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Aug 1;65(5):1345-52 [16750315.001]
  • [Cites] Clin Plast Surg. 2007 Jan;34(1):29-37; abstract v-vi [17307069.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1282-90 [17275207.001]
  • [Cites] Plast Reconstr Surg. 2004 Sep 15;114(4):950-60 [15468404.001]
  • (PMID = 18707822.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / KL2 RR024149-01; None / None / / KL2 RR024149-02; None / None / / KL2 RR024149-01; United States / NCRR NIH HHS / RR / KL2 RR024149; United States / NCRR NIH HHS / RR / KL2 RR024149-02
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS269607; NLM/ PMC3041273
  •  go-up   go-down


29. Peters GN, Fodera T, Sabol J, Jones S, Euhus D: Estrogen replacement therapy after breast cancer: a 12-year follow-up. Ann Surg Oncol; 2001 Dec;8(10):828-32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen replacement therapy after breast cancer: a 12-year follow-up.
  • BACKGROUND: In the United States, estrogen replacement therapy (ERT) is discouraged in breast cancer survivors because of concerns that hormones may reactivate the disease.
  • Medical records for these patients were analyzed for disease stage, surgical treatment, adjuvant treatment, estrogen and progesterone receptor status, date of initiation of ERT, type of ERT, recurrence, and final outcome.
  • The median time on ERT since diagnosis was 6.4 years (range, 1.0-20.9 years); 38% of the patients initiated ERT within 2 years of diagnosis.
  • Pathological disease stage at time of diagnosis and treatment was 0 in 15 cases (27%), I in 27 (48%), and II in 14 (25%).
  • Twenty-six patients (47%) received adjuvant chemotherapy or hormonal therapy.
  • [MeSH-major] Breast Neoplasms. Carcinoma, Ductal, Breast. Carcinoma, Lobular. Estrogen Replacement Therapy / utilization. Estrogens, Conjugated (USP) / administration & dosage

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11776498.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens, Conjugated (USP)
  •  go-up   go-down


30. Maughan KL, Lutterbie MA, Ham PS: Treatment of breast cancer. Am Fam Physician; 2010 Jun 1;81(11):1339-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of breast cancer.
  • Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment.
  • This article reviews typical treatments based on stage, histology, and biomarkers.
  • Lobular carcinoma in situ does not require treatment.
  • Ductal carcinoma in situ can progress to invasive cancer and is treated with breast-conserving surgery and radiation therapy without further lymph node exploration or systemic therapy.
  • Stages I and II breast cancers are usually treated with breast-conserving surgery and radiation therapy.
  • Radiation therapy following breast-conserving surgery decreases mortality and recurrence.
  • Choice of adjuvant systemic therapy depends on lymph node involvement, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, and patient age and menopausal status.
  • In general, node-positive breast cancer is treated systemically with chemotherapy, endocrine therapy (for hormone receptor-positive cancer), and trastuzumab (for cancer overexpressing ERBB2).
  • Stage III breast cancer typically requires induction chemotherapy to downsize the tumor to facilitate breast-conserving surgery.
  • Inflammatory breast cancer, although considered stage III, is aggressive and requires induction chemotherapy followed by mastectomy, rather than breastconserving surgery, as well as axillary lymph node dissection and chest wall radiation.
  • Prognosis is poor in women with recurrent or metastatic (stage IV) breast cancer, and treatment options must balance benefits in length of life and reduced pain against harms from treatment.
  • [MeSH-major] Breast Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Humans. Mastectomy. Neoplasm Staging. Sentinel Lymph Node Biopsy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am Fam Physician. 2010 Jun 1;81(11):1330-2 [20521750.001]
  • [CommentIn] Am Fam Physician. 2011 Mar 1;83(5):507; author reply 507 [21391515.001]
  • [CommentIn] Am Fam Physician. 2011 Mar 1;83(5):502-6; author reply 507 [21391514.001]
  • [CommentIn] Am Fam Physician. 2010 Jun 1;81(11):1347-9 [20527363.001]
  • (PMID = 20521754.001).
  • [ISSN] 1532-0650
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


31. d'Annibale M, Piovanello P, Cerasoli V, Campioni N: Liver metastases from breast cancer: the role of surgical treatment. Hepatogastroenterology; 2005 Nov-Dec;52(66):1858-62
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastases from breast cancer: the role of surgical treatment.
  • BACKGROUND/AIMS: To evaluate short- and long-term outcomes in the surgical treatment of liver metastases from breast cancer METHODOLOGY: Between 1984 and 1999 we observed 26 patients with secondary liver localization (25 metachronous) from breast cancer.
  • Median age at the time of liver surgery was 56 years (36-76).
  • The 18 patients included: 1 patient at stage 1, 10 at IIA, 6 stage II B and 1 patient at stage IV.
  • Fifteen patients had infiltrating ductal carcinoma, 2 a lobular carcinoma and 1 patient a mixed-component carcinoma.
  • In 9 cases the patients underwent adjuvant chemotherapy (5 of them following postoperative radiotherapy) and in 14 cases Tamoxifen was used.
  • Nine patients died; six patients are still living, 4 of them "disease-free", 2 having advanced metastatic disease, in treatment.
  • The overall 5-year-survival was 25% in patients whose liver metastases developed within 3 years after breast surgery compared with 40% in those ones with metastatic disease diagnosed more than 3 years after.
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Palliative Care. Retrospective Studies. Risk Assessment. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334793.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement